<!DOCTYPE html>
<html lang="zh-CN">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>ğŸ§¬ PubMed RNA Editing Daily Digest</title>
  <style>
    body {
      font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', system-ui, sans-serif;
      background: #050816;
      color: #e5e7eb;
      margin: 0;
      padding: 1.5rem;
      max-width: 900px;
      margin-inline: auto;
    }
    header {
      margin-bottom: 2rem;
      border-bottom: 1px solid #1f2937;
      padding-bottom: 1.5rem;
    }
    h1 {
      margin: 0 0 .5rem;
      font-size: 1.9rem;
    }
    .desc {
      color: #9ca3af;
      font-size: .95rem;
    }
    .date {
      margin-top: .75rem;
      color: #a5b4fc;
      font-weight: 500;
    }
    .count {
      font-size: .9rem;
      color: #9ca3af;
      margin-top: .25rem;
    }
    .archive-top {
      margin-top: .5rem;
      font-size: .9rem;
    }
    .archive-top a {
      color: #a5b4fc;
      text-decoration: none;
    }
    .paper-card {
      background: #020617;
      border-radius: .75rem;
      border: 1px solid #1f2937;
      padding: 1.25rem 1.4rem;
      margin-bottom: 1rem;
    }
    .paper-header {
      display: flex;
      justify-content: space-between;
      align-items: center;
      margin-bottom: .4rem;
      font-size: .8rem;
      color: #9ca3af;
      gap: .75rem;
    }
    .paper-header .left {
      display: flex;
      align-items: center;
      gap: .5rem;
    }
    .journal {
      text-transform: uppercase;
      letter-spacing: .08em;
    }
    .date {
      font-variant-numeric: tabular-nums;
    }
    .score-badge {
      border-radius: 999px;
      border: 1px solid #4f46e5;
      padding: 0.15rem 0.6rem;
      font-size: 0.78rem;
      color: #a5b4fc;
      background: rgba(79, 70, 229, 0.12);
    }
    .title {
      margin: .2rem 0 .4rem;
      font-size: 1.05rem;
      line-height: 1.4;
    }
    .title a {
      color: #e5e7eb;
      text-decoration: none;
    }
    .title a:hover {
      color: #a5b4fc;
    }
    .title-zh {
      margin: 0 0 .4rem;
      color: #9ca3af;
      font-size: .92rem;
    }
    .authors {
      margin: 0 0 .7rem;
      color: #9ca3af;
      font-size: .85rem;
    }
    .summary {
      background: #020617;
      border-radius: .5rem;
      border: 1px solid #1f2937;
      padding: .7rem .8rem;
      font-size: .86rem;
      margin-bottom: .5rem;
    }
    .summary-block {
      margin-bottom: .35rem;
    }
    .summary-block:last-child {
      margin-bottom: 0;
    }
    .summary-block strong {
      color: #a5b4fc;
      margin-right: .25rem;
    }
    details.abstract {
      margin-top: .3rem;
      font-size: .85rem;
    }
    details.abstract summary {
      cursor: pointer;
      color: #9ca3af;
    }
    details.abstract p {
      margin-top: .4rem;
      color: #9ca3af;
    }
    footer {
      margin-top: 2rem;
      padding-top: 1.5rem;
      border-top: 1px solid #1f2937;
      font-size: .8rem;
      color: #6b7280;
    }
    footer a {
      color: #a5b4fc;
      text-decoration: none;
    }
  </style>
</head>
<body>
  <header>
    <h1>ğŸ§¬ PubMed RNA Editing Daily Digest</h1>
    <p class="desc">æœ€è¿‘ 30 å¤©å†…å¯ç¼–ç¨‹ RNA ç¼–è¾‘ / gRNA å·¥ç¨‹å·¥å…·ç›¸å…³è®ºæ–‡ç²¾é€‰</p>
    <div class="date">ğŸ“… 2026-02-14</div>
    <div class="count">å…± 5 ç¯‡ç²¾é€‰è®ºæ–‡</div>
    <div class="archive-top"><a href="archive.html">æŸ¥çœ‹å†å²å½’æ¡£ â†’</a></div>
  </header>

  <main>
  <article class="paper-card">
  <div class="paper-header">
    <div class="left">
      <span class="journal">Biosensors & bioelectronics</span>
      <span class="date">2026-02-12</span>
    </div>
    <span class="score-badge">ç›¸å…³æ€§ 45/100</span>
  </div>
  <h3 class="title">
    <a href="https://pubmed.ncbi.nlm.nih.gov/41679990/" target="_blank">Highly fluorescent copper nanoclusters as programmable reporters for CRISPR/Cas12a-based detection of bacterial DNA.</a>
  </h3>
  <p class="title-zh">åŸºäºCRISPR/Cas12aå’Œé“œçº³ç±³ç°‡çš„é«˜è§å…‰å¯ç¼–ç¨‹ç»†èŒDNAæ£€æµ‹æŠ¥å‘Šç³»ç»Ÿ</p>
  <p class="authors">Carota AG, Spiaggia F, Poma N, Palladino P, Cuffaro D, Vivaldi F, Ravelet C, Di Francesco F</p>
  <div class="summary">
    <div class="summary-block"><strong>å·¥å…·ç±»å‹:</strong> RNAä¼ æ„Ÿå™¨/CRISPRè¯Šæ–­å¹³å°ï¼ˆå…·ä½“ä¸ºDNAæ£€æµ‹å·¥å…·ï¼Œä½†æ ¸å¿ƒä¾èµ–äºCRISPR/Cas12açš„RNAå¼•å¯¼ç¼–ç¨‹æ€§ï¼‰</div>
    <div class="summary-block"><strong>åŠŸèƒ½ä¸åº”ç”¨:</strong> 1. **å¯ç¼–ç¨‹çš„æ ¸é…¸åˆ†å­æ£€æµ‹**ï¼šé€šè¿‡è®¾è®¡gRNAåºåˆ—ï¼Œå¯ç‰¹å¼‚æ€§æ£€æµ‹ä¸åŒçš„é¶æ ‡ç»†èŒDNAã€‚
2. **è§å…‰ä¿¡å·æŠ¥å‘Š**ï¼šåˆ©ç”¨DNAæ¨¡æ¿CuNCsçš„è§å…‰å˜åŒ–ï¼ˆä¿¡å·å…³é—­æ¨¡å¼ï¼‰æ¥ç›´è§‚æŠ¥å‘Šæ£€æµ‹ç»“æœã€‚
3. **é€‚ç”¨äºå³æ—¶æ£€æµ‹**ï¼šè¯¥å¹³å°å…·æœ‰æˆæœ¬ä½ã€æ­¥éª¤ç®€å•ï¼ˆä¸€é”…æ³•ï¼‰ã€æ— éœ€è§å…‰åŸºå›¢-æ·¬ç­åŸºå›¢æ¢é’ˆçš„ç‰¹ç‚¹ï¼Œé€‚åˆç°åœºéƒ¨ç½²ã€‚</div>
    <div class="summary-block"><strong>å…³é”®ç»“æœ:</strong> 1. **æ€§èƒ½ä¼˜å¼‚**ï¼šè¯¥æ£€æµ‹å¹³å°è¾¾åˆ°äº†çš®æ‘©å°”çº§åˆ«çš„çµæ•åº¦ï¼Œå¹¶èƒ½å‡†ç¡®æ£€æµ‹æ¥è‡ªå‚è€ƒèŒæ ªã€ä¸´åºŠåˆ†ç¦»æ ªä»¥åŠè¡€æ¸…åŠ æ ‡æ ·æœ¬ä¸­çš„å¤§è‚ æ†èŒDNAã€‚
2. **ä¿¡å·å“åº”æ˜¾è‘—**ï¼šä¼˜åŒ–åçš„å¯Œå«ATèŒç¯æŠ¥å‘Šæ¨¡æ¿èƒ½äº§ç”Ÿå¼ºè§å…‰ä¿¡å·ï¼Œå¹¶åœ¨é¶æ ‡è¯†åˆ«åè¢«Cas12aå®Œå…¨åˆ‡å‰²ï¼Œå®ç°è§å…‰ä¿¡å·çš„å®Œå…¨å…³é—­ï¼Œä¿¡å™ªæ¯”é«˜ã€‚</div>
  </div>
  <details class="abstract">
    <summary>æŸ¥çœ‹æ‘˜è¦</summary>
    <p>Early and accessible pathogen detection is crucial for global health security and demands diagnostic assays that are rapid, affordable, and suitable for Point-of-Care use. This study presents a cost-effective, rapid, one-pot fluorescence assay for bacterial DNA detection that exploits the unique optical properties of DNA-templated copper nanoclusters (CuNCs). These nanoclusters offer a sustainable alternative to conventional fluorophores, thanks to their eco-friendly synthesis, high photostability, and large Stokes shift. The assay integrates CuNCs with the CRISPR/Cas12a system to achieve programmable and highly specific target recognition. Upon target binding, activation of the Cas12a/gRNA complex triggers collateral cleavage of rationally designed DNA templates that normally support CuNCs formation, resulting in a marked fluorescence decrease. A panel of hairpin and poly-thymine DNA structures was systematically evaluated to maximize both CuNCs fluorescence and responsiveness to Cas12a/gRNA trans-cleavage, ultimately identifying an AT-rich stem-loop reporter that provided strong signal intensity and complete signal shutdown upon target recognition. The final CRISPR-CuNCs assay achieved picomolar sensitivity, accurately detected E. coli DNA from reference strains, clinical isolates, and serum-spiked samples, and required no fluorophore-quencher probes or multistep procedures. Overall, this work demonstrated that combining the programmability of CRISPR/Cas12a with the versatility and low-cost of DNA-templated CuNCs enables a robust and accessible platform for molecular diagnostics, with strong potential for Point-of-Care deployment.</p>
  </details>
</article>

<article class="paper-card">
  <div class="paper-header">
    <div class="left">
      <span class="journal">bioRxiv : the preprint server for biology</span>
      <span class="date">2026-02-02</span>
    </div>
    <span class="score-badge">ç›¸å…³æ€§ 45/100</span>
  </div>
  <h3 class="title">
    <a href="https://pubmed.ncbi.nlm.nih.gov/41684938/" target="_blank">Genome-wide screening reveals producer-cell modifications that improve virus-like particle production and delivery potency.</a>
  </h3>
  <p class="title-zh">å…¨åŸºå› ç»„ç­›é€‰æ­ç¤ºæé«˜ç—…æ¯’æ ·é¢—ç²’ç”Ÿäº§ä¸é€’é€æ•ˆåŠ›çš„ç”Ÿäº§è€…ç»†èƒæ”¹é€ ç­–ç•¥</p>
  <p class="authors">Ly D, Jang H, Goel A, Singh A, Raguram A</p>
  <div class="summary">
    <div class="summary-block"><strong>å·¥å…·ç±»å‹:</strong> ç—…æ¯’æ ·é¢—ç²’ï¼ˆeVLPï¼‰ç”Ÿäº§å¹³å°ä¼˜åŒ–å·¥å…· / ç”Ÿäº§è€…ç»†èƒå·¥ç¨‹ç­›é€‰å¹³å°</div>
    <div class="summary-block"><strong>è®¾è®¡æ€è·¯:</strong> 1. å¼€å‘äº†ä¸€ç§å…¨åŸºå› ç»„ç­›é€‰æ–¹æ³•ï¼Œé€šè¿‡è®©ç”Ÿäº§è€…ç»†èƒæºå¸¦ä¸åŒçš„é—ä¼ æ‰°åŠ¨ï¼ˆå¦‚åŸºå› æ•²é™¤/è¿‡è¡¨è¾¾ï¼‰ï¼Œå¹¶ç”Ÿäº§è£…è½½æœ‰å¯¹åº”gRNAçš„eVLPã€‚
2. åˆ©ç”¨gRNAä½œä¸ºâ€œæ¡å½¢ç â€ï¼Œé€šè¿‡æµ‹å®šeVLPä¸­ä¸åŒgRNAçš„ä¸°åº¦ï¼Œåå‘æ¨ç®—å‡ºç”Ÿäº§è€…ç»†èƒä¸­ç‰¹å®šçš„é—ä¼ æ‰°åŠ¨å¯¹eVLPäº§é‡æˆ–è´§ç‰©è£…è½½æ•ˆç‡çš„å½±å“ã€‚</div>
    <div class="summary-block"><strong>åŠŸèƒ½ä¸åº”ç”¨:</strong> 1. **é«˜é€šé‡ç­›é€‰åŠŸèƒ½**ï¼šç³»ç»Ÿæ€§é‰´å®šèƒ½ä¼˜åŒ–eVLPç”Ÿäº§çš„å®¿ä¸»ç»†èƒåŸºå› é¶ç‚¹ã€‚
2. **å¹³å°ä¼˜åŒ–åŠŸèƒ½**ï¼šæŒ‡å¯¼å¯¹ç”Ÿäº§è€…ç»†èƒè¿›è¡Œå·¥ç¨‹åŒ–æ”¹é€ ï¼Œä»¥æå‡eVLPçš„è´§ç‰©åŒ…è£…æ•ˆç‡å’Œé€’é€æ•ˆåŠ›ã€‚
3. **åº”ç”¨æ‰©å±•åŠŸèƒ½**ï¼šä½œä¸ºé€šç”¨ç­–ç•¥ï¼Œå¯ç”¨äºæ”¹å–„åŸºäºeVLPçš„åŸºå› ç¼–è¾‘å‰‚æˆ–å…¶ä»–è´§ç‰©çš„é€’é€ç³»ç»Ÿã€‚</div>
    <div class="summary-block"><strong>å…³é”®ç»“æœ:</strong> 1. æˆåŠŸé‰´å®šå‡ºå¤šä¸ªåœ¨eVLPç”Ÿäº§è¿‡ç¨‹ä¸­è°ƒæ§è´§ç‰©è¡¨è¾¾ä¸è£…è½½çš„å®¿ä¸»åŸºå› ã€‚
2. åŸºäºç­›é€‰ç»“æœæ”¹é€ ç”Ÿäº§è€…ç»†èƒåï¼Œä½¿eVLPçš„è´§ç‰©åŒ…è£…å¢åŠ ï¼Œå¹¶åœ¨å¤šç§è´§ç‰©ã€é¢—ç²’åŠé¶ç»†èƒç±»å‹ä¸­ï¼Œå°†eVLPçš„é€’é€æ•ˆåŠ›ï¼ˆåœ¨åŸ¹å…»ç»†èƒå’Œå°é¼ ä½“å†…ï¼‰æé«˜äº†2è‡³9å€ã€‚</div>
  </div>
  <details class="abstract">
    <summary>æŸ¥çœ‹æ‘˜è¦</summary>
    <p>Engineered virus-like particles (eVLPs) are promising vehicles for transient delivery of gene editing agents. While extensive particle engineering has yielded efficient eVLPs, it remains underexplored whether engineering the cells used to produce eVLPs could further improve eVLP properties. We developed a genome-wide screening approach to systematically investigate how genetic perturbations in producer cells influence eVLP production. This approach generates eVLPs loaded with guide RNAs that identify the genetic perturbation in the cell that produced a particular particle; the abundance of each guide RNA in eVLPs therefore reflects how the corresponding genetic perturbation influences eVLP production or cargo loading. We applied this approach to identify several genes that regulate eVLP cargo expression and loading into particles during the production process. Leveraging these insights, we engineered producer cells that support increased eVLP cargo packaging and a 2- to 9-fold increase in eVLP delivery potency across several cargo, particle, and target-cell types in cultured cells and in mice. Our findings suggest the potential of producer-cell engineering as a useful strategy for improving the utility of eVLPs and related delivery methods.</p>
  </details>
</article>

<article class="paper-card">
  <div class="paper-header">
    <div class="left">
      <span class="journal">The CRISPR journal</span>
      <span class="date">2026-02-01</span>
    </div>
    <span class="score-badge">ç›¸å…³æ€§ 45/100</span>
  </div>
  <h3 class="title">
    <a href="https://pubmed.ncbi.nlm.nih.gov/41338874/" target="_blank">BAR-CAT: Targeted Recovery of Synthetic Genes via Barcode-Directed CRISPR-dCas9 Enrichment.</a>
  </h3>
  <p class="title-zh">BAR-CATï¼šé€šè¿‡æ¡å½¢ç å¼•å¯¼çš„CRISPR-dCas9å¯Œé›†å®ç°åˆæˆåŸºå› çš„é¶å‘å›æ”¶</p>
  <p class="authors">Villegas NK, Tran MH, Keller A, Plesa C</p>
  <div class="summary">
    <div class="summary-block"><strong>å·¥å…·ç±»å‹:</strong> åŸºäºCRISPR-dCas9çš„åŸºå› æ–‡åº“ç­›é€‰ä¸å›æ”¶å¹³å°</div>
    <div class="summary-block"><strong>è®¾è®¡æ€è·¯:</strong> è¯¥å·¥å…·çš„æ ¸å¿ƒè®¾è®¡æ€è·¯æ˜¯å°†åˆæˆåŸºå› ä¸ç‹¬ç‰¹æ¡å½¢ç ï¼ˆBarcodeï¼‰è¿›è¡Œç‰©ç†è¿æ¥ï¼Œå¹¶åˆ©ç”¨dCas9è›‹ç™½ä¸æ¡å½¢ç ç‰¹å¼‚æ€§gRNAçš„é¶å‘ç»“åˆï¼Œå®ç°å¯¹æ–‡åº“ä¸­æºå¸¦æ­£ç¡®æ¡å½¢ç ï¼ˆå³å¯¹åº”æ— é”™è¯¯åˆæˆåŸºå› ï¼‰çš„DNAåˆ†å­è¿›è¡Œç‰¹å¼‚æ€§å¯Œé›†ä¸å›æ”¶ã€‚å…¶æ¨¡å—åŒ–ç»„åˆåŒ…æ‹¬ï¼šåˆæˆåŸºå› -æ¡å½¢ç å…³è”æ¨¡å—ã€dCas9-gRNAé¶å‘è¯†åˆ«æ¨¡å—ä»¥åŠåç»­çš„å¯Œé›†/æ‰©å¢å›æ”¶æ¨¡å—ã€‚</div>
    <div class="summary-block"><strong>åŠŸèƒ½ä¸åº”ç”¨:</strong> 1. ä»åŒ…å«åˆæˆé”™è¯¯çš„å¤æ‚åŸºå› æ–‡åº“ä¸­ï¼Œé«˜æ•ˆã€ç‰¹å¼‚æ€§åœ°å›æ”¶åºåˆ—æ­£ç¡®çš„å®Œæ•´åˆæˆåŸºå› ã€‚
2. ä½œä¸ºé«˜é€šé‡åŸºå› åˆæˆå·¥ä½œæµçš„è´¨æ§ä¸çº¯åŒ–ç¯èŠ‚ï¼Œæå‡é•¿ç‰‡æ®µåŸºå› åˆæˆçš„æˆåŠŸç‡ä¸æ–‡åº“è´¨é‡ã€‚
3. å¯ç”¨äºåŠŸèƒ½æ€§åŸºå› ç­›é€‰å®éªŒä¸­ï¼Œå¯¹ç›®æ ‡è¡¨å‹å¯¹åº”çš„å®Œæ•´åŸºå› åºåˆ—è¿›è¡Œå®šå‘åˆ†ç¦»ä¸è·å–ã€‚</div>
    <div class="summary-block"><strong>å…³é”®ç»“æœ:</strong> å…³é”®å®éªŒè¡¨æ˜ï¼ŒBAR-CATèƒ½å¤Ÿä»é”™è¯¯ç‡éšé•¿åº¦å¢åŠ çš„åˆæˆåŸºå› æ–‡åº“ä¸­ï¼Œå°†æ— é”™è¯¯å…¨é•¿åŸºå› çš„å›æ”¶ç‡æé«˜è¶…è¿‡100å€ï¼›åœ¨é’ˆå¯¹é•¿åº¦ä¸º1.5 kbçš„ç»¿è‰²è§å…‰è›‹ç™½ï¼ˆGFPï¼‰åŸºå› çš„å›æ”¶å®éªŒä¸­ï¼ŒæˆåŠŸå¯Œé›†å¹¶æ¢å¤äº†å…·æœ‰å®Œæ•´åŠŸèƒ½çš„GFPåºåˆ—ï¼ŒéªŒè¯äº†å…¶åœ¨ä½“å¤–åº”ç”¨ä¸­çš„é«˜æ•ˆæ€§ä¸ç‰¹å¼‚æ€§ã€‚</div>
  </div>
  <details class="abstract">
    <summary>æŸ¥çœ‹æ‘˜è¦</summary>
    <p>Modern gene synthesis platforms enable investigations of protein function and genome biology at an unprecedented scale. Yet, the proportion of error-free constructs in diverse gene libraries decreases with length due to the propagation of oligo synthesis errors. To rescue these error-free constructs, we developed Barcode-Assisted Retrieval CRISPR-Activated Targeting (BAR-CAT), an</p>
  </details>
</article>

<article class="paper-card">
  <div class="paper-header">
    <div class="left">
      <span class="journal">International journal of molecular sciences</span>
      <span class="date">2026-01-30</span>
    </div>
    <span class="score-badge">ç›¸å…³æ€§ 45/100</span>
  </div>
  <h3 class="title">
    <a href="https://pubmed.ncbi.nlm.nih.gov/41683838/" target="_blank">A Translational Roadmap for Neurological Nonsense Mutation Disorders.</a>
  </h3>
  <p class="title-zh">ç¥ç»æ€§æ— ä¹‰çªå˜ç–¾ç—…çš„è½¬åŒ–è·¯çº¿å›¾</p>
  <p class="authors">Li J, Zhu Z, Xu S</p>
  <div class="summary">
    <div class="summary-block"><strong>å·¥å…·ç±»å‹:</strong> è½¬åŒ–æ¡†æ¶/ç»¼è¿°ï¼ˆéå•ä¸€å·¥å…·ï¼Œè€Œæ˜¯æ•´åˆäº†å¤šç§RNAé¶å‘æ²»ç–—å¹³å°çš„ç­–ç•¥æ€§è·¯çº¿å›¾ï¼‰</div>
    <div class="summary-block"><strong>è®¾è®¡æ€è·¯:</strong> æœ¬æ–‡æå‡ºä¸€ä¸ªåä¸ºâ€œé€šè¯»ç–—æ³•çš„4Dæ¡†æ¶â€çš„è½¬åŒ–ç­–ç•¥ï¼Œå…¶æ ¸å¿ƒè®¾è®¡æ€è·¯æ˜¯å°†å¤æ‚çš„æ²»ç–—æµç¨‹æ¨¡å—åŒ–ä¸ºå››ä¸ªå…³é”®ç¯èŠ‚ï¼šæ£€æµ‹ã€é€’é€ã€è§£ç å’ŒæŒä¹…æ€§ã€‚è¯¥æ¡†æ¶æ—¨åœ¨ç³»ç»Ÿæ€§åœ°æ•´åˆæœºå™¨å­¦ä¹ ã€çº³ç±³è½½ä½“ã€ç¢±åŸºç¼–è¾‘å’Œé€‚åº”æ€§ä¸´åºŠè¯•éªŒè®¾è®¡ç­‰å¤šç§å‰æ²¿æŠ€æœ¯ï¼Œä»¥å…‹æœä»åŸºç¡€ç ”ç©¶åˆ°ä¸´åºŠåº”ç”¨çš„éšœç¢ã€‚</div>
    <div class="summary-block"><strong>åŠŸèƒ½ä¸åº”ç”¨:</strong> è¯¥æ¡†æ¶æ—¨åœ¨æŒ‡å¯¼å’Œä¼˜åŒ–é’ˆå¯¹æ— ä¹‰çªå˜ï¼ˆPTCsï¼‰çš„å„ç±»æ²»ç–—å·¥å…·çš„åº”ç”¨ï¼Œå…¶æ•´åˆçš„å·¥å…·å¹³å°å¯å®ç°ä»¥ä¸‹åŠŸèƒ½ï¼š
1. ç²¾å‡†æ‚£è€…è¯†åˆ«ä¸ç”Ÿç‰©æ ‡å¿—ç‰©åˆ†æï¼ˆDetectionï¼‰ã€‚
2. ä¸­æ¢ç¥ç»ç³»ç»Ÿé¶å‘é€’é€ï¼ˆDeliveryï¼‰ã€‚
3. åŸºäºæƒ…å¢ƒæ„ŸçŸ¥çš„åˆ†å­çŸ«æ­£ï¼ŒåŒ…æ‹¬é€šè¯»æ— ä¹‰å¯†ç å­ä»¥æ¢å¤å…¨é•¿è›‹ç™½è¡¨è¾¾ï¼ˆDecodingï¼‰ã€‚
4. è¯„ä¼°é•¿æœŸå®‰å…¨æ€§ä¸ç–—æ•ˆï¼ˆDurabilityï¼‰ã€‚</div>
    <div class="summary-block"><strong>å…³é”®ç»“æœ:</strong> æœ¬æ–‡æ˜¯ä¸€ç¯‡ç»¼è¿°ï¼ŒæœªæŠ¥å‘Šå…·ä½“çš„å®éªŒæ•°æ®ã€‚å…¶æ ¸å¿ƒè´¡çŒ®åœ¨äºæå‡ºäº†ä¸€ä¸ªç»“æ„åŒ–çš„è½¬åŒ–ç­–ç•¥æ¡†æ¶ï¼Œæ—¨åœ¨ç³»ç»Ÿæ€§åœ°è§£å†³å½“å‰æ— ä¹‰çªå˜ç–—æ³•ï¼ˆå¦‚æŠ‘åˆ¶æ€§tRNAã€RNAç¼–è¾‘ã€CRISPRå¹³å°ç­‰ï¼‰åœ¨ä¸´åºŠè½¬åŒ–ä¸­é¢ä¸´çš„é€’é€æ•ˆç‡ä½ã€ç–—æ•ˆä¸ä¸€å’Œç¼ºä¹ä¸ªæ€§åŒ–åˆ†å±‚ç­‰å…³é”®ç“¶é¢ˆã€‚</div>
  </div>
  <details class="abstract">
    <summary>æŸ¥çœ‹æ‘˜è¦</summary>
    <p>Nonsense mutations, responsible for ~11% of gene lesions causing human monogenic diseases, introduce premature termination codons (PTCs) that lead to truncated proteins and nonsense-mediated mRNA decay (NMD). In the central nervous system (CNS), these mutations drive severe, progressive neurological conditions such as spinal muscular atrophy, Rett syndrome, and Duchenne muscular dystrophy. Readthrough therapies-strategies to override PTCs and restore full-length protein expression-have evolved from early aminoglycosides to modern precision tools including suppressor tRNAs, RNA editing, and CRISPR-based platforms. Yet clinical translation remains hampered by inefficient CNS delivery, variable efficacy, and the absence of personalized stratification. In this review, we propose a translational framework-the 4 Ds of Readthrough Therapy-to systematically address these barriers. The framework dissects the pipeline into Detection (precision patient identification and biomarker profiling), Delivery (engineered vectors for CNS targeting), Decoding (context-aware molecular correction), and Durability (long-term safety and efficacy). By integrating advances in machine learning, nanocarriers, base editing, and adaptive trial designs, this roadmap provides a structured strategy to bridge the translational gap. We advocate that a synergistic, modality-tailored approach will transform nonsense suppression from palliative care to durable, precision-based cures for once-untreatable neurological disorders.</p>
  </details>
</article>

<article class="paper-card">
  <div class="paper-header">
    <div class="left">
      <span class="journal">Communications biology</span>
      <span class="date">2026-02-11</span>
    </div>
    <span class="score-badge">ç›¸å…³æ€§ 35/100</span>
  </div>
  <h3 class="title">
    <a href="https://pubmed.ncbi.nlm.nih.gov/41673115/" target="_blank">RNA editing in cardiovascular health and disease.</a>
  </h3>
  <p class="title-zh">RNAç¼–è¾‘åœ¨å¿ƒè¡€ç®¡å¥åº·ä¸ç–¾ç—…ä¸­çš„ä½œç”¨</p>
  <p class="authors">Huang X, Solomon C, McVey DG, Ye S</p>
  <div class="summary">
    <div class="summary-block"><strong>å·¥å…·ç±»å‹:</strong> ç»¼è¿°/å±•æœ›æ–‡ç« ï¼ˆéå…·ä½“å·¥å…·ï¼Œä½†æ¢è®¨äº†åŸºäºADARçš„RNAç¼–è¾‘ä½œä¸ºæ²»ç–—å¹³å°çš„æ½œåŠ›ï¼‰</div>
    <div class="summary-block"><strong>è®¾è®¡æ€è·¯:</strong> æœ¬æ–‡å¹¶éä»‹ç»ä¸€ä¸ªå…·ä½“çš„å·¥ç¨‹åŒ–å·¥å…·ï¼Œè€Œæ˜¯ç»¼è¿°äº†å†…æºæ€§ADARé…¶ä»‹å¯¼çš„A-to-I RNAç¼–è¾‘åœ¨å¿ƒè¡€ç®¡ç³»ç»Ÿä¸­çš„ç”Ÿç‰©å­¦ä½œç”¨ï¼Œå¹¶å±•æœ›äº†å°†å…¶å·¥ç¨‹åŒ–ä¸ºæ²»ç–—å¹³å°çš„æ€è·¯ã€‚æ ¸å¿ƒæ€è·¯æ˜¯åˆ©ç”¨æˆ–æ”¹é€ ADARé…¶ï¼ˆæˆ–ç±»ä¼¼æœºåˆ¶ï¼‰ï¼Œé€šè¿‡ç‰¹å¼‚æ€§é¶å‘ï¼ˆå¦‚ä½¿ç”¨äº’è¡¥å¯¡æ ¸è‹·é…¸ï¼‰æ¥é‡ç¼–ç¨‹RNAç¼–è¾‘äº‹ä»¶ï¼Œä»è€Œçº æ­£ç–¾ç—…ç›¸å…³çš„å¼‚å¸¸ç¼–è¾‘æˆ–å¼•å…¥æ²»ç–—æ€§ç¼–è¾‘ã€‚</div>
    <div class="summary-block"><strong>åŠŸèƒ½ä¸åº”ç”¨:</strong> 1. **åŸºç¡€ç ”ç©¶å·¥å…·**ï¼šè§£æå†…æºæ€§A-to-I RNAç¼–è¾‘åœ¨å¿ƒè¡€ç®¡å‘è‚²ã€ç¨³æ€å’Œç–¾ç—…ï¼ˆå¦‚å¿ƒè‚Œç—…ã€åŠ¨è„‰ç²¥æ ·ç¡¬åŒ–ã€å¿ƒåŠ›è¡°ç«­ï¼‰ä¸­çš„åŠŸèƒ½ã€‚
2. **ç–¾ç—…ç”Ÿç‰©æ ‡å¿—ç‰©å¼€å‘å¹³å°**ï¼šåˆ©ç”¨å¼‚å¸¸RNAç¼–è¾‘è°±ä½œä¸ºå¿ƒè¡€ç®¡ç–¾ç—…çš„è¯Šæ–­æˆ–é¢„åæ ‡å¿—ç‰©ã€‚
3. **æ½œåœ¨æ²»ç–—å¹³å°**ï¼šé€šè¿‡å·¥ç¨‹åŒ–æ‰‹æ®µï¼ˆå¦‚å¯¼å‘RNAè®¾è®¡ï¼‰å®ç°ä½ç‚¹ç‰¹å¼‚æ€§RNAç¼–è¾‘ï¼Œä»¥çº æ­£è‡´ç—…æ€§çªå˜æˆ–è°ƒèŠ‚åŸºå› è¡¨è¾¾ï¼Œç”¨äºå¿ƒè¡€ç®¡ç–¾ç—…æ²»ç–—ã€‚</div>
    <div class="summary-block"><strong>å…³é”®ç»“æœ:</strong> æœ¬æ–‡æ˜¯ä¸€ç¯‡ç»¼è¿°ï¼ŒæœªæŠ¥å‘Šå…·ä½“çš„å®éªŒæ•°æ®ã€‚å…¶å…³é”®ç»“è®ºåœ¨äºç³»ç»Ÿæ€»ç»“äº†**å†…æºæ€§A-to-Iç¼–è¾‘åœ¨å¿ƒè¡€ç®¡ç³»ç»Ÿä¸­çš„å…³é”®ä½œç”¨**ï¼Œå¹¶è®ºè¯äº†**å°†RNAç¼–è¾‘æŠ€æœ¯å¹³å°åŒ–ç”¨äºå¿ƒè¡€ç®¡ç–¾ç—…è¯Šæ–­å’Œæ²»ç–—å…·æœ‰å·¨å¤§æ½œåŠ›**ï¼Œä¸ºåç»­å·¥å…·å¼€å‘æä¾›äº†ç†è®ºä¾æ®å’Œåº”ç”¨æ–¹å‘ã€‚</div>
  </div>
  <details class="abstract">
    <summary>æŸ¥çœ‹æ‘˜è¦</summary>
    <p>Post-transcriptional RNA modifications can alter RNA structure, stability, localization, and function. Adenosine-to-inosine (A-to-I) RNA editing is a post-transcriptional modification that converts adenosine nucleotides in RNA to inosine nucleotides, catalyzed by adenosine-deaminase-acting-on-RNA (ADAR) enzymes. Recent studies have shown that A-to-I RNA editing is required for cardiovascular development and homeostasis whilst aberrant RNA editing plays a role in cardiovascular diseases. This article provides an overview of A-to-I RNA editing events that have been implicated in cardiovascular biology and disease. It also discusses harnessing RNA editing for cardiovascular disease biomarker development and engineering RNA editing for cardiovascular disease treatment.</p>
  </details>
</article>
  </main>

  <footer>
    <p>æ•°æ®æ¥æº: <a href="https://pubmed.ncbi.nlm.nih.gov/" target="_blank">PubMed</a></p>
    <p>AI æ’åº/æ€»ç»“: DeepSeek</p>
  </footer>
</body>
</html>
